Eton Pharmaceuticals, Inc. Amortization of Intangible Assets
Eton Pharmaceuticals, Inc. (ETON) reported Amortization of Intangible Assets of $2.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $1.36M, a 36.26% increase year-over-year.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $1.11M, a 10.79% increase year-over-year.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $1.00M, a 191.55% increase year-over-year.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $1.00M, a 274.91% increase year-over-year.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2025 was $4.00M, a 265.24% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2024 was $1.10M, a 38.73% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2023 was $790.00K, a 51.14% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2022 was $1.62M, a 692.65% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.47M 10-Q · filed 2026-08-13 | $3.47M derived: sum of 3 quarters · filed 2026-08-13 | $4.47M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $1.11M 10-Q · filed 2026-05-14 | $2.11M derived: sum of 2 quarters · filed 2026-05-14 | $3.11M derived: sum of 3 quarters · filed 2026-05-14 | $4.11M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.00M derived: sum of 2 quarters · filed 2026-03-19 | $3.00M derived: sum of 3 quarters · filed 2026-08-13 | $4.00M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.00M derived: sum of 2 quarters · filed 2026-08-13 | $3.00M 10-Q · filed 2025-11-06 | $3.35M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.00M 10-Q · filed 2026-08-13 | $2.35M derived: sum of 3 quarters · filed 2026-08-13 | $2.61M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-14 | $1.34M derived: sum of 2 quarters · filed 2026-05-14 | $1.61M derived: sum of 3 quarters · filed 2026-05-14 | $1.88M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $610.00K derived: sum of 2 quarters · filed 2026-03-19 | $877.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.10M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $267.00K 10-Q · filed 2024-11-12 | $534.00K derived: sum of 2 quarters · filed 2024-11-12 | $753.00K 10-Q · filed 2025-11-06 | $1.00M derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-06-30 | $267.00K 10-Q · filed 2024-08-08 | $487.00K 10-Q · filed 2025-08-07 | $733.00K derived: sum of 3 quarters · filed 2026-03-19 | $915.00K derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-03-31 | $220.00K 10-Q · filed 2025-05-13 | $466.00K derived: sum of 2 quarters · filed 2026-03-19 | $648.00K derived: sum of 3 quarters · filed 2026-03-19 | $829.00K derived: sum of 4 quarters · filed 2026-03-19 | |
| 2023-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $428.00K derived: sum of 2 quarters · filed 2026-03-19 | $609.00K derived: sum of 3 quarters · filed 2026-03-19 | $790.00K 10-K · filed 2026-03-19 | |
| 2023-09-30 | $182.00K 10-Q · filed 2023-11-09 | $363.00K derived: sum of 2 quarters · filed 2023-11-09 | $544.00K 10-Q · filed 2023-11-09 | $763.00K derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-06-30 | $181.00K 10-Q · filed 2023-08-10 | $362.00K 10-Q · filed 2023-08-10 | $581.00K derived: sum of 3 quarters · filed 2025-03-18 | $716.00K derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-03-31 | $181.00K 10-Q · filed 2024-05-09 | $181.00 10-Q · filed 2023-05-11 | $400.00K derived: sum of 2 quarters · filed 2025-03-18 | $535.00K derived: sum of 3 quarters · filed 2025-03-18 | $536.13K derived: sum of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $354.00K derived: sum of 2 quarters · filed 2025-03-18 | $355.13K derived: sum of 3 quarters · filed 2025-03-18 | $1.62M 10-K · filed 2025-03-18 | |
| 2022-09-30 | $135.00K 10-Q · filed 2022-11-10 | $136.13K derived: sum of 2 quarters · filed 2022-11-10 | $1.40M 10-Q · filed 2022-11-10 | $228.26K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $1.13K 10-Q · filed 2022-08-11 | $1.26K 10-Q · filed 2022-08-11 | $93.26K derived: sum of 3 quarters · filed 2024-03-14 | $130.26K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $131.00 10-Q · filed 2023-05-11 | $131.00K 10-Q · filed 2022-05-12 | $92.13K derived: sum of 2 quarters · filed 2024-03-14 | $129.13K derived: sum of 3 quarters · filed 2024-03-14 | $166.13K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $129.00K derived: sum of 2 quarters · filed 2024-03-14 | $166.00K derived: sum of 3 quarters · filed 2024-03-14 | $204.00K 10-K · filed 2024-03-14 | |
| 2021-09-30 | $37.00K 10-Q · filed 2021-11-16 | $74.00K derived: sum of 2 quarters · filed 2021-11-16 | $112.00K 10-Q · filed 2021-11-16 | ||
| 2021-06-30 | $37.00K 10-Q · filed 2021-08-16 | $75.00K 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $38.00K 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $150.00K 10-K · filed 2023-03-16 | ||||
| 2019-12-31 | $25.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |